HighTower Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

HighTower Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,880	Closed	-$37.6K	–	3981
2024 Q4	$37.6K	Hold	24,880	–	–	﹤0.01%	3486
2024 Q3	$37K	Sell	24,880 -150	-0.6%	-$232	﹤0.01%	3446
2024 Q2	$40K	Hold	25,030	–	–	﹤0.01%	3330
2024 Q1	$42K	Hold	25,030	–	–	﹤0.01%	3277
2023 Q4	$77K	Hold	25,030	–	–	﹤0.01%	3245
2023 Q3	$154K	Hold	25,030	–	–	﹤0.01%	3002
2023 Q2	$157K	Hold	25,030	–	–	﹤0.01%	2949
2023 Q1	$120K	Sell	25,030 -198	-0.8%	-$1.39K	﹤0.01%	2903
2022 Q4	$219K	Buy	25,228 +198	+0.8%	+$2.11K	﹤0.01%	2707
2022 Q3	$298K	Buy	25,030 +150	+0.6%	+$2.17K	﹤0.01%	2341
2022 Q2	$355K	Hold	24,880	–	–	﹤0.01%	2250
2022 Q1	$518K	Hold	24,880	–	–	﹤0.01%	2145
2021 Q4	$575K	Buy	+24,880	New	+$601K	﹤0.01%	2059

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors's PMVP Position: Q1 2025 in Review

HighTower Advisors sold out of PMV Pharmaceuticals (PMVP) in Q1 2025, closing a stake of 24,880 shares — an estimated $37.6K sold.

HighTower Advisors first reported a position in PMVP in Q4 2021 and held it in 13 quarters. The position peaked at $575K in Q4 2021. 55 funds tracked by Wall St. Rank hold PMVP as of Q1 2025.

HighTower Advisors reported no remaining PMV Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
HighTower Advisors sold 24,880 PMV Pharmaceuticals shares in Q1 2025, an estimated $37.6K.
HighTower Advisors first reported a position in PMV Pharmaceuticals in Q4 2021 and held it in 13 quarters.
HighTower Advisors's PMV Pharmaceuticals position peaked at $575K in Q4 2021.
55 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.